Cocaine catalytic antibodies: the primary importance of linker effects.
Current treatments for cocaine addiction are not effective. The development of a catalytic monoclonal antibody (mAb) provides a strategy for not only binding, but also degrading cocaine, which offers a broad-based therapy. Hapten design is the central element for programming antibody catalysis. The characteristics of the linker used in classic transition-state analogue phosphonate haptens were shown to be important for obtaining mAbs that hydrolyze the benzoate ester of cocaine.
Matsushita
M
M
The Scripps Research Institute and the Skaggs Institute for Chemical Biology, Department of Chemistry, La Jolla, CA 92037, USA.
Hoffman
T Z
TZ
Ashley
J A
JA
Zhou
B
B
Wirsching
P
P
Janda
K D
KD
D000818:Animals; D017151:Antibodies, Catalytic / Q000378:metabolism* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000627:therapeutic use; D003042:Cocaine / Q000276:immunology* / Q000378:metabolism; D019970:Cocaine-Related Disorders / Q000188:drug therapy; D015195:Drug Design; D006241:Haptens / Q000737:chemistry; D006868:Hydrolysis; D007700:Kinetics; D051379:Mice; D063065:Organophosphonates / Q000737:chemistry; D013329:Structure-Activity Relationship
D017151:Antibodies, Catalytic; D000911:Antibodies, Monoclonal; D006241:Haptens; D063065:Organophosphonates; D003042:Cocaine